
---
nice.evidencecategory: 
---

### Evidence Statement CG66ES124
One RCT257 with a follow-up of 2.6 years, found that treatment with irbesartan significantly
reduced the risk of doubling serum creatinine concentration, development of ESRD, or death
from any cause, by 23% compared to the amlodipine therapy (p=0.006). Level 1++

[@Remuzzi_2004]

